GT200600126A - Oblea que contiene hormonas estoides - Google Patents

Oblea que contiene hormonas estoides

Info

Publication number
GT200600126A
GT200600126A GT200600126A GT200600126A GT200600126A GT 200600126 A GT200600126 A GT 200600126A GT 200600126 A GT200600126 A GT 200600126A GT 200600126 A GT200600126 A GT 200600126A GT 200600126 A GT200600126 A GT 200600126A
Authority
GT
Guatemala
Prior art keywords
hormones
steroid
stioid
oblea
almidon
Prior art date
Application number
GT200600126A
Other languages
English (en)
Spanish (es)
Inventor
Markus Krume
Sascha General
Albert Radlmaier
Michael Dittgen
Keith Jensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36998911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600126(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600126A publication Critical patent/GT200600126A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT200600126A 2005-03-31 2006-03-27 Oblea que contiene hormonas estoides GT200600126A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005015128A DE102005015128B4 (de) 2005-03-31 2005-03-31 Wafer enthaltend Steroidhormone

Publications (1)

Publication Number Publication Date
GT200600126A true GT200600126A (es) 2007-03-14

Family

ID=36998911

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600126A GT200600126A (es) 2005-03-31 2006-03-27 Oblea que contiene hormonas estoides

Country Status (26)

Country Link
US (2) US9763960B2 (enExample)
EP (1) EP1863444B1 (enExample)
JP (2) JP5843416B2 (enExample)
KR (2) KR20140063740A (enExample)
CN (2) CN104983669B (enExample)
AR (1) AR054245A1 (enExample)
AU (1) AU2006228820B2 (enExample)
BR (1) BRPI0609601A2 (enExample)
CA (1) CA2598892C (enExample)
CR (1) CR9468A (enExample)
DE (1) DE102005015128B4 (enExample)
DO (1) DOP2006000070A (enExample)
EA (1) EA014183B1 (enExample)
GT (1) GT200600126A (enExample)
IL (1) IL186081A0 (enExample)
MX (1) MX2007012081A (enExample)
NO (1) NO20075404L (enExample)
NZ (1) NZ592882A (enExample)
PE (1) PE20061194A1 (enExample)
SG (1) SG179459A1 (enExample)
SV (1) SV2008002466A (enExample)
TW (1) TWI393576B (enExample)
UA (1) UA92011C2 (enExample)
UY (1) UY29441A1 (enExample)
WO (1) WO2006102990A2 (enExample)
ZA (1) ZA200706116B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
NZ586666A (en) * 2008-02-13 2012-04-27 Bayer Schering Pharma Ag Estradiol-containing drug delivery system
KR20100117603A (ko) * 2008-02-13 2010-11-03 바이엘 쉐링 파마 악티엔게젤샤프트 안정화 효과를 갖는 약물 전달 시스템
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
CA2744127A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
EP2493457B1 (en) 2009-10-30 2017-08-09 IX Biopharma Ltd Fast dissolving solid dosage form
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
AU2012385956B2 (en) 2012-07-23 2017-03-30 Crayola, Llc Dissolvable films and methods of using the same
DE102017112527B4 (de) * 2017-06-07 2019-01-03 Lts Lohmann Therapie-Systeme Ag Schnell zerfallende Schaumwafer mit hohem Flächengewicht
MX2020008147A (es) * 2018-02-02 2020-10-28 Acerus Biopharma Inc Metodos de terapia de testosterona.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981372A (en) * 1960-05-04 1965-01-27 Pfizer Ltd Pharmaceutical formulations for oral administration to animals
US4136162A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
DE69312487T2 (de) * 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DE19847252B4 (de) * 1998-10-02 2004-02-12 Jenapharm Gmbh & Co. Kg Bukkal applizierbare bioadhäsive Systeme mit zeitlich gesteuerter Wirkstofffreisetzung enthaltend Testosteronester und fakultativ zusätzlich Testosteron
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
AU2001273231A1 (en) * 2000-07-06 2002-01-21 Delsys Pharmaceutical Corporation Method for formulating healthcare products with enhanced stability
GB0100760D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
FR2832311B1 (fr) * 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
JP2007500729A (ja) * 2003-07-31 2007-01-18 アイバックス コーポレイション 雄性及び雌性の性機能障害の治療方法
PL1670433T3 (pl) * 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze

Also Published As

Publication number Publication date
JP2013155190A (ja) 2013-08-15
EA200702102A1 (ru) 2008-04-28
WO2006102990A2 (de) 2006-10-05
JP5843416B2 (ja) 2016-01-13
TW200714299A (en) 2007-04-16
US9763960B2 (en) 2017-09-19
AU2006228820B2 (en) 2011-08-25
SV2008002466A (es) 2008-02-08
ZA200706116B (en) 2008-11-26
KR20140063740A (ko) 2014-05-27
EP1863444A2 (de) 2007-12-12
JP2008534533A (ja) 2008-08-28
US20060222708A1 (en) 2006-10-05
CN104983669A (zh) 2015-10-21
BRPI0609601A2 (pt) 2010-04-20
NZ592882A (en) 2012-12-21
KR20080002798A (ko) 2008-01-04
SG179459A1 (en) 2012-04-27
TWI393576B (zh) 2013-04-21
CN101132766A (zh) 2008-02-27
DE102005015128B4 (de) 2008-12-11
CN104983669B (zh) 2018-05-18
EP1863444B1 (de) 2015-12-09
PE20061194A1 (es) 2006-11-23
US20170348321A1 (en) 2017-12-07
DE102005015128A1 (de) 2006-10-05
NO20075404L (no) 2007-12-20
AU2006228820A1 (en) 2006-10-05
MX2007012081A (es) 2007-11-21
WO2006102990A3 (de) 2007-03-22
IL186081A0 (en) 2008-01-20
KR101428625B1 (ko) 2014-08-13
UA92011C2 (ru) 2010-09-27
DOP2006000070A (es) 2007-08-15
AR054245A1 (es) 2007-06-13
EA014183B1 (ru) 2010-10-29
CR9468A (es) 2008-01-21
CA2598892C (en) 2014-10-14
UY29441A1 (es) 2006-10-31
CA2598892A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
GT200600126A (es) Oblea que contiene hormonas estoides
UY30109A1 (es) Formas farmacológicas en forma de película para usar en la cavidad bucal (obleas)
BRPI0819235A2 (pt) Sistema de distribuição transdérmica para hormônios e esteróides
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2007002594A1 (es) Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
CR10612A (es) Anticuerpo especifico prlr y sus usos
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
MX2007015424A (es) Formulaciones ungueales topicas.
UY26496A1 (es) Composiciones farmacéuticas que proporcionan concentraciones potenciadas de fármaco
CL2017001952A1 (es) Composiciones estables de povidona-yodo con esteroides o antiinflamatorios no esteroideos (divisional solicitud 592-2014)
AR067441A1 (es) Aromatizador de ambiente con apoyo
CL2009000550A1 (es) Metodo para mantener el estado de latencia de una semilla y evitar la germinacion de la misma que comprende revestir dicha semilla con una composicion que comprende particulas que contienen un material de nucleo, el cual comprende un material de cambio de fase.
CR7610A (es) Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona
CR9763A (es) Uso de una sola dosis de moleculas de union especificas cd20
PL2179100T3 (pl) Płuczka WC z przesuniętym w czasie uwalnianiem dwóch substancji biologicznie aktywnych
CL2011003172A1 (es) Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos.
AR066527A1 (es) Panel para la contruccion de edificios con salientes perpendiculares a una cara
NO20080002L (no) Formuleringer av konjugerte ostrogener og bazedoxifen
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
CL2008000617A1 (es) Composicion farmaceutica que comprende a un agente calcilitico adminstrado oralmente, induce liberacion rapida y de corta duracion de la hormona paratiroide en el plasma; y proceso para la preparacion de la composicion farmaceutica.
CL2011000073A1 (es) Uso de compuestos derivados de pirimidil-amino-benzamida; composicion farmaceutica ; y su uso en el tratamiento de fibrosis hepatica y fibrosis pulmonar.